Robinsonklitgaard8815

Objectives To investigate the full publication proportion (FPP) of abstracts presented at the 2010 and 2011 EAO Congresses, analyse the discrepancies between abstracts and their full publications, and explore potential predictors of FPP and discrepancies. Methods Abstracts presented at the 2010 and 2011 EAO Congresses were retrieved. Associated full publications were identified by searching PubMed, Embase and Google Scholar. Discrepancies between abstracts and full publications were identified, classified and evaluated using a discrepancy score. The Kaplan-Meier survival analysis was used to describe cumulative FPP over time. Predictors for FPP and the discrepancy score were analysed using cox regression modelling and a linear regression model, respectively. Results 850 abstracts were included. The overall FPP was 36.4% with a median time lapse of 12 months. Higher FPP were significantly associated with oral presentation (HR=2.33; 95% CI 1.68 to 3.22; p less then 0.001), multiple affiliations (HR =1.32; 95% CI 1.00 to 1.73; p=0.048) and presence of statistical tests (HR =1.78; 95% CI 1.36 to 2.32; p less then 0.001). 91.3% pairs had at least one minor change from the abstract and 70.9% had at least one major change. Greater discrepancy score was significantly associated with longer time lapse (B=0.06; 95% CI 0.04 to 0.08; p less then 0.001) and being clinical research (B=1.30; 95% CI 0.52 to 2.08; p=0.001). Conclusions Thirty-six percent of abstracts presented at the EAO Congresses were published. selleckchem Among these, more than two-thirds showed at least one major change in their full publications. Abstracts presented in oral implantology conferences should not be relied upon to inform practice.There are currently thousands of offshore platforms in place for oil and gas extraction worldwide, and decommissioning efforts over the next 3 decades are estimated to cost more than $200 billion USD. As platforms reach the end of their useful lifetime, operators and regulatory agencies will assess the environmental impact of potential decommissioning strategies. Among the many factors that will be weighed in preparation for these major economic and engineering challenges is the fate of the fish and invertebrate communities that inhabit the structures underwater. Offshore platforms act as inadvertent artificial reefs, and some are recognized among the most productive fish habitats in the global oceans. We present a model for forecasting changes to fish communities surrounding offshore installations following a series of decommissioning alternatives. Using 24 platforms off southern California, we estimate fish biomass and somatic production under three possible decommissioning scenarios leave in place, partialtakeholder interests, the site-specific biomass, productivity and species composition information provided in this study should be incorporated into strategic decommissioning planning. This approach could be used as a model for informing "rigs to reefs" discussions occurring worldwide.There is an increasing interest in transporter induction (i.e., decreased systemic drug exposure due to increased efflux-limited absorption or transporter-mediated clearance) as a mechanism of drug-drug interactions (DDIs), although evidence of clinical relevance is still evolving. Intestinal P-glycoprotein (P-gp) and hepatic organic anion transporting polypeptides 1B (OATP1B) can be important determinants of drug absorption and disposition, as well as targets for DDIs. Current data indicate that intestinal P-gp protein levels can be induced ≤3-4 fold in humans primarily with pregnane X receptor (PXR) activators, and that this induction can decrease the systemic exposure of drugs with P-gp efflux-limited absorption (e.g., ≤67% decrease in the exposure of total dabigatran following rifampin multiple oral dosing). Evaluation of the clinical relevance of P-gp induction as a DDI mechanism must consider the induction potential of the perpetrator drug for P-gp and attenuation of exposure of the victim drug in the context of its therapeutic window. Practical drug development recommendations are provided herein. Reports are contradictory on OATP1B induction by PXR activators in human hepatocytes and liver biopsies. Some clinical investigations demonstrated that rifampin pretreatment decreased exposure of OATP1B substrates, while other studies found no differences, and the potential involvement of other mechanisms in these observed DDIs cannot be definitively ruled out. Thus, further studies are needed to understand hepatic OATP1B induction and potential involvement of other mechanisms contributing to reduced exposure of OATP1B substrates. This review critically summarizes the state-of-the-art on intestinal P-gp and hepatic OATP1B induction, and highlights implications for drug development.Coronavirus disease 19 (Covid‐19) was declared a pandemic by the World Health Organization on March 11th, 2020 (https//www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen). As of May 19th, 2020, approximately 4,731,458 cases of contamination and 316,169 deaths from Covid‐19 were recorded (https//who.sprinklr.com).Creatinine is an important diagnostic marker and is also used as a standardization tool for the quantitative evaluation of exogenous/endogenous substances in urine. This study aimed at evaluating and comparing three analytical approaches, based on hyphenations of different separation [two-dimensional capillary isotachophoresis (CITP-CITP), capillary zone electrophoresis (CZE), ultra-high-performance liquid chromatography (UHPLC)] and detection [conductivity (CD), ultraviolet (UV), tandem mass spectrometry (MS/MS)] techniques, for their ability to provide reliable clinical data along with their suitability for the routine clinical use (cost, simplicity, sample throughput). The developed UHPLC-MS/MS, CITP-CITP-CD, and CZE-UV methods were characterized by favorable performance parameters, such as linearity (r ˃ 0.99), precision (relative standard deviation, 0.22-2.97% for the creatinine position in analytical profiles), and recovery (87.1-115.1%). Clinical data, obtained from the analysis of 24 human urine samples by a reference enzymatic method, were comparable with those obtained by the tested methods (Passing-Bablok regression and Bland-Altman analysis), approving their usefulness for the routine clinical use.